Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 3
2009 3
2010 9
2011 12
2012 6
2013 6
2014 20
2015 24
2016 27
2017 35
2018 43
2019 27
2020 52
2021 50
2022 49
2023 64
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Results by year

Filters applied: . Clear all
Page 1
Drugging KRAS: current perspectives and state-of-art review.
Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, Addeo A. Parikh K, et al. Among authors: subbiah v. J Hematol Oncol. 2022 Oct 25;15(1):152. doi: 10.1186/s13045-022-01375-4. J Hematol Oncol. 2022. PMID: 36284306 Free PMC article. Review.
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Wirth LJ, et al. Among authors: subbiah v. N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651. N Engl J Med. 2020. PMID: 32846061 Free PMC article. Clinical Trial.
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJ. Subbiah V, et al. Nat Med. 2023 May;29(5):1103-1112. doi: 10.1038/s41591-023-02321-8. Epub 2023 Apr 14. Nat Med. 2023. PMID: 37059834 Free PMC article. Clinical Trial.
Variant allele frequency: a decision-making tool in precision oncology?
Boscolo Bielo L, Trapani D, Repetto M, Crimini E, Valenza C, Belli C, Criscitiello C, Marra A, Subbiah V, Curigliano G. Boscolo Bielo L, et al. Among authors: subbiah v. Trends Cancer. 2023 Dec;9(12):1058-1068. doi: 10.1016/j.trecan.2023.08.011. Epub 2023 Sep 12. Trends Cancer. 2023. PMID: 37704501 Review.
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Subbiah V, Sahai V, Maglic D, Bruderek K, Touré BB, Zhao S, Valverde R, O'Hearn PJ, Moustakas DT, Schönherr H, Gerami-Moayed N, Taylor AM, Hudson BM, Houde DJ, Pal D, Foster L, Gunaydin H, Ayaz P, Sharon DA, Goyal L, Schram AM, Kamath S, Sherwin CA, Schmidt-Kittler O, Jen KY, Ricard F, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Casaletto JB. Subbiah V, et al. Cancer Discov. 2023 Sep 6;13(9):2012-2031. doi: 10.1158/2159-8290.CD-23-0475. Cancer Discov. 2023. PMID: 37270847 Free PMC article.
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Trigo J, et al. Among authors: subbiah v. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Lancet Oncol. 2020. PMID: 32224306 Clinical Trial.
Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, Besse B. Drilon A, et al. Among authors: subbiah v. J Clin Oncol. 2023 Jan 10;41(2):385-394. doi: 10.1200/JCO.22.00393. Epub 2022 Sep 19. J Clin Oncol. 2023. PMID: 36122315 Free PMC article. Clinical Trial.
406 results